• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Neogen Announces Preliminary¹ Second-Quarter 2025 Results

    1/10/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NEOG alert in real time by email
    • Revenue of $231.3 million.
    • Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share.
    • Adjusted Net Income2 of $24.4 million; $0.11 per diluted share.
    • Adjusted EBITDA2 of $51.4 million.
    • Updating full-year guidance.

    LANSING, Mich., Jan. 10, 2025 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) announced today the preliminary results of the second quarter ended November 30, 2024.

    Neogen Corporation (PRNewsfoto/Neogen Corporation)

    "The second quarter reflected steady progress, as we saw improvement across the business compared to the first quarter, with core revenue growth accelerating in both of our segments, sequential margin expansion and significantly better free cash flow," said John Adent, Neogen's President and Chief Executive Officer. "In our Food Safety segment, we did see continued gradual improvement in the end market as it works through largely unprecedented times stemming from the significant inflation in food prices and resulting lower levels of food production. This gradual end-market improvement has coincided with what we see as an increasing focus on food safety from both regulators and consumers, driven in part by numerous recent food contamination incidents. While we're not reliant on the regulatory environment to drive growth, the increased regulatory interest highlights not only the importance of food safety overall, but also the room for improvement that exists. In our Animal Safety segment, we saw a significant improvement in core revenue growth from the first quarter despite the end market being around what we believe is a cyclical low point. Inventory levels in the distribution channel appear to be low, but we are encouraged by the growth in sales of our products out of the channel in the quarter."            

    Adent continued, "While our primary focus has shifted to winning in the market, we have also undertaken actions to accelerate the building of a more profitable, focused Neogen. During the second quarter, we initiated restructuring actions focused mainly on rightsizing our Genomics business to focus our end-market exposure and streamline our operations. We expect these actions, combined with cost reductions related to our logistics operations, to support continued margin improvement in the second half of the fiscal year. We have also entered the next phase of portfolio review with specific projects actively underway and will evaluate any potential opportunities that arise to drive a higher level of focus in the business and improved profitability. The significant progress we've made notwithstanding, the integration of the former 3M Food Safety business has been slowed by a combination of end-market weakness and operational delays. We continue to have full confidence in the post-integration prospects of the business and, with the food safety end market showing gradual improvement and our share recapture progressing well, we intend to build on the progress we made in the second quarter in building Neogen for the future and positioning the company to win in the market."

    Financial and Business Highlights

    Revenues for the second quarter were $231.3 million, an increase of 0.7% compared to $229.6 million in the prior year. Core revenue2, which excludes the impacts of foreign currency translation, as well as acquisitions completed and product lines discontinued in the last 12 months, increased by 3.5%. Acquisitions and discontinued product lines had a negative impact of 0.3% while foreign currency had a negative impact of 2.5%.

    Net loss for the second quarter was $456.3 million, or $(2.10) per diluted share, compared to net loss of $3.5 million, or $(0.02) per diluted share, in the prior-year period, with the current-year net loss driven by a non-cash goodwill impairment charge related primarily to the acquisition of the former 3M Food Safety Division. Adjusted Net Income was $24.4 million, or $0.11 per diluted share, compared to $24.9 million, or $0.11 per diluted share, in the prior-year period. The slight decline in Adjusted Net Income was driven primarily by the lower level of operating income, mostly offset by a more favorable effective tax rate.

    Gross margin was 49.0% in the second quarter of fiscal 2025. This compares to a gross margin of 50.9% in the same quarter a year ago, with the decrease mainly due to restructuring costs. Excluding integration and restructuring costs, gross margin was 52.2% in the second quarter compared to 52.3% in the prior-year quarter.

    Second-quarter Adjusted EBITDA was $51.4 million, representing an Adjusted EBITDA Margin of 22.2%, compared to $55.1 million and a margin of 24.0% in the prior-year period. The decline in Adjusted EBITDA Margin was driven primarily by the full cost to exit the various transition service agreements that had been in place, including higher distribution costs.

    Food Safety Segment

    Revenues for the Food Safety segment were $164.2 million in the second quarter, a decrease of 0.1% compared to $164.4 million in the prior year, consisting of 3.6% core growth, a negative 0.1% impact from discontinued product lines and a negative foreign currency impact of 3.6%. The core growth was driven largely by a solid performance in the biosecurity and bacterial & general sanitation product categories. In the indicator testing, culture media & other product category, solid growth in food quality, culture media and Petrifilm was partially offset by a decline in sample collection. Within the natural toxins & allergens product category, modest growth in allergens was partially offset by a slight decline in natural toxins.

    Animal Safety Segment

    Revenues for the Animal Safety segment were $67.0 million in the second quarter, an increase of 2.8% compared to $65.2 million in the prior year, consisting of a 3.2% core growth, a favorable 0.3% foreign currency impact and a negative 0.7% impact from discontinued product lines. The growth was led by the biosecurity and animal care & other product categories, particularly rodent control biologics and wound care products.

    On a global basis, the Company's Genomics business experienced a core revenue decline in the mid-single-digit range. Increased sales in U.S. and international beef and dairy markets were offset by lower sales in the companion animal market.

    Internal Controls

    As a result of management's assessment of the Company's internal control over financial reporting, the Company concluded that, as of November 30, 2024, the Company had deficiencies in the control activities and information and communication components of the COSO Framework that constitute material weaknesses. More information regarding these control deficiencies and the material weakness will be contained within the Company's Form 10-Q to be filed for the quarter ended November 30, 2024.

    Liquidity and Capital Resources

    As of November 30, 2024, the Company had total cash of $140.2 million and total outstanding non-current debt of $900.0 million, as well as committed borrowing headroom of $150.0 million.

    Preliminary Nature of Reported Results

    The information provided in this release is preliminary in nature because the analysis of the non-cash goodwill impairment charge described above has not been completed. The Company does not currently expect the estimated amount of that charge to change; however, the preliminary results presented in this release are subject to change as the Company finalizes its condensed consolidated financial statements for the second quarter of fiscal 2025. The Company expects to file its Form 10-Q for such quarter by Wednesday, January 15, 2025.

    Fiscal Year 2025 Outlook

    The Company is updating its full-year outlook. Primarily due to the strengthening of the U.S. dollar and, to a lesser degree, a delay in the ramp-up of sample collection production and the voluntary attrition of genomics revenue related to restructuring activities, revenue is now expected to be in the range of $905 million to $925 million. Adjusted EBITDA is now expected to be in the range of $205 million to $215 million, primarily reflecting the impact of lower revenue and higher shipping and distribution costs. The Company continues to expect capital expenditures to be approximately $85 million, including approximately $55 million related specifically to the integration of the former 3M Food Safety Division.

    Conference Call and Webcast

    Neogen Corporation will host a conference call today at 8:00 a.m. Eastern Time to discuss the Company's financial results. The live webcast of the conference call and accompanying presentation materials can be accessed through Neogen's website at neogen.com/investor-relations. For those unable to access the webcast, the conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646) 357-8785 (International) and requesting the Neogen Corporation Second Quarter 2025 Earnings Call. A replay of the conference call and webcast will be available shortly following the conclusion of the call, and can be accessed domestically or internationally by dialing (888) 660-6345 or +1 (646) 517-4150, respectively, and providing the entry code 39384#, or through Neogen's Investor Relations website at neogen.com/investor-relations.

    About Neogen

    Neogen is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen Corporation has developed comprehensive solutions spanning the Food Safety, Livestock and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

    Cautionary Note Regarding Forward-Looking Statements

    Statements in this news release that are not historical facts constitute forward-looking statements. These forward-looking statements are subject to significant risks and uncertainties. Actual future results and trends may differ materially from historical results and from those currently expected depending on a variety of factors, including those risk factors described in the company's most recently filed Form 10-K, as may be updated by subsequent SEC filings. In addition, the finalization of our interim goodwill impairment analysis, the possibility that the company will not be able to file its Form 10-Q within the five-day extension period permitted by SEC rules, and the occurrence of subsequent events are other factors that could cause actual results to be different than the forward-looking statements included in this press release. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, the company does not undertake, and expressly disclaims, any obligation to update any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions, or otherwise.

    1 Results presented in this release are preliminary and unaudited estimates based on information currently available to the Company. Such results could differ from the final amounts the Company reports in its Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2024. The Company assumes no obligation, and does not intend, to update these estimates prior to filing its Form 10-Q.

    2 Non-GAAP financial measures; see explanations and reconciliations that follow.

     

    NEOGEN CORPORATION

    UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS

    (In thousands, except for share and per share amounts)

    (Preliminary Unaudited)







    Three months ended November 30,





    Six months ended November 30,







    2024





    2023





    2024





    2023



    Revenue

























    Food Safety



    $

    164,238





    $

    164,403





    $

    323,583





    $

    330,681



    Animal Safety





    67,020







    65,226







    124,639







    127,935



    Total revenue





    231,258







    229,629







    448,222







    458,616



    Cost of revenues





    117,928







    112,855







    229,966







    225,081



    Gross profit





    113,330







    116,774







    218,256







    233,535



    Operating expenses

























    Sales & marketing





    46,545







    44,832







    92,344







    90,615



    Administrative





    57,771







    51,721







    109,442







    96,842



    Goodwill impairment





    461,390







    —







    461,390







    —



    Research & development





    5,108







    5,756







    10,307







    12,478



    Total operating expenses





    570,814







    102,309







    673,483







    199,935



    Operating (loss) income





    (457,484)







    14,465







    (455,227)







    33,600



    Interest expense, net





    (17,367)







    (16,169)







    (34,989)







    (32,835)



    Other expense





    (1,721)







    (2,043)







    (1,965)







    (2,849)



    Loss before tax





    (476,572)







    (3,747)







    (492,181)







    (2,084)



    Income tax benefit





    (20,290)







    (260)







    (23,290)







    (100)



    Net loss



    $

    (456,282)





    $

    (3,487)





    $

    (468,891)





    $

    (1,984)



    Net loss per diluted share



    $

    (2.10)





    $

    (0.02)





    $

    (2.16)





    $

    (0.01)



    Shares to calculate per share amount





    216,813,788







    216,410,493







    216,754,244







    216,359,511



     

    NEOGEN CORPORATION

    UNAUDITED CONSOLIDATED BALANCE SHEET

    (In thousands, except share amounts)

    (Preliminary Unaudited)











    November 30, 2024





    May 31, 2024



    Assets













    Current Assets













    Cash and cash equivalents



    $

    140,231





    $

    170,611



    Marketable securities





    —







    325



    Accounts receivable, net of allowance of $4,833 and $4,140





    164,086







    173,005



    Inventories, net of reserves of $19,505 and $12,361





    198,267







    189,267



    Prepaid expenses and other current assets





    67,863







    56,025



    Total Current Assets





    570,447







    589,233



    Net Property and Equipment





    310,552







    277,104



    Other Assets













    Right of use assets





    17,201







    14,785



    Goodwill





    1,672,501







    2,135,632



    Intangible assets, net





    1,463,163







    1,511,653



    Other non-current assets





    20,228







    20,426



    Total Assets



    $

    4,054,092





    $

    4,548,833



    Liabilities and Stockholders' Equity













    Current Liabilities













    Current portion of finance lease



    $

    2,576





    $

    2,447



    Accounts payable





    79,574







    83,061



    Accrued compensation





    16,480







    19,949



    Income tax payable





    11,176







    10,449



    Accrued interest





    11,091







    10,985



    Deferred revenue





    5,651







    4,632



    Other accruals





    24,647







    22,800



    Total Current Liabilities





    151,195







    154,323



    Deferred Income Tax Liability





    302,405







    326,718



    Non-current debt





    889,867







    888,391



    Other non-current liabilities





    41,555







    35,259



    Total Liabilities





    1,385,022







    1,404,691



    Commitments and Contingencies













    Equity













    Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding





    —







    —



    Common stock, $0.16 par value, 315,000,000 shares authorized, 216,944,017 and

    216,614,407 shares issued and outstanding





    34,712







    34,658



    Additional paid-in capital





    2,592,374







    2,583,885



    Accumulated other comprehensive loss





    (44,745)







    (30,021)



    Retained earnings





    86,729







    555,620



    Total Stockholders' Equity





    2,669,070







    3,144,142



    Total Liabilities and Stockholders' Equity



    $

    4,054,092





    $

    4,548,833



     

    NEOGEN CORPORATION

    UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In thousands)

    (Preliminary Unaudited)







    Six months ended November 30,







    2024





    2023



    Cash Flows provided by Operating Activities













    Net loss



    $

    (468,891)





    $

    (1,984)



    Adjustments to reconcile net loss to net cash from operating activities:













    Depreciation and amortization





    59,849







    58,203



    Deferred income taxes





    (23,924)







    1,178



    Share-based compensation





    8,801







    6,150



    Loss on disposal of property and equipment





    164







    38



    Amortization of debt issuance costs





    1,720







    1,720



    Goodwill and other asset impairment





    468,718







    716



    Other





    (261)







    —



    Change in operating assets and liabilities, net of business acquisitions:













    Accounts receivable, net





    5,332







    3,633



    Inventories, net





    (17,398)







    (25,929)



    Prepaid expenses and other current assets





    (16,675)







    (29,896)



    Accounts payable and accrued liabilities





    2,166







    34,950



    Interest expense accrual





    106







    (164)



    Change in other non-current assets and non-current liabilities





    2,632







    (9,892)



    Net Cash provided by Operating Activities





    22,339







    38,723



    Cash Flows (used for) provided by Investing Activities













    Purchases of property, equipment and other non-current intangible assets





    (55,590)







    (55,046)



    Proceeds from the maturities of marketable securities





    325







    57,828



    Proceeds from the sale of property and equipment and other





    4,446







    70



    Net Cash (used for) provided by Investing Activities





    (50,819)







    2,852



    Cash Flows (used for) provided by Financing Activities













    Exercise of stock options and issuance of employee stock purchase plan shares





    1,182







    1,230



    Tax payments related to share-based awards





    (1,439)







    (89)



    Repayment of finance lease and other





    (173)







    (389)



    Net Cash (used for) provided by Financing Activities





    (430)







    752



    Effects of Foreign Exchange Rate on Cash





    (1,470)







    198



    Net (Decrease) Increase in Cash and Cash Equivalents





    (30,380)







    42,525



    Cash and Cash Equivalents, Beginning of Year





    170,611







    163,240



    Cash and Cash Equivalents, End of Year



    $

    140,231





    $

    205,765



    Supplemental cash flow information













    Right of use assets obtained in exchange for new operating lease liabilities



    $

    5,802





    $

    2,198



    Non-GAAP Financial Measures

    This press release includes certain non-GAAP financial measures, which management believes are useful to investors, securities analysts and other interested parties. The following description of the non-GAAP financial measures included in this release, as well as the information included within the reconciliation tables on the pages that follow, refer to GAAP and non-GAAP financial measures on a preliminary, expected basis only.

    Management uses Adjusted EBITDA as a key profitability measure. This is a non-GAAP measure that represents EBITDA before certain items that impact comparison of the performance of our business period-over-period. Adjusted EBITDA Margin is Adjusted EBITDA for a particular period expressed as a percentage of revenues for that period.

    Management uses Adjusted Net Income as an additional measure of profitability. Adjusted Net Income is a non-GAAP measure that represents net income before certain items that impact comparison of the performance of our business period-over-period.

    Core revenue growth is a non-GAAP measure that represents net sales for the period excluding the effects of foreign currency translation rates and the first-year impacts of acquisitions and discontinued product lines, where applicable. Core revenue growth is presented to allow for a meaningful comparison of year-over-year performance without the volatility caused by foreign currency translation rates, or the incomparability that would be caused by the impact of an acquisition, disposal or product line discontinuation.

    These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP. Please see below for a reconciliation of historical non-GAAP financial measures used in this press release to the most directly comparable financial measures prepared in accordance with GAAP.

    The Company is not presenting a reconciliation of the forward-looking non-GAAP financial measure, Adjusted EBITDA, to the most directly comparable GAAP financial measure, Net Income (Loss), because it is impractical to forecast certain items without unreasonable efforts. This is due to the uncertainty and inherent difficulty of predicting, within a reasonable range, the occurrence and financial impact of and the periods in which such items may be recognized, including adjustments that are made for future changes in foreign exchange and the other adjustments reflected in our reconciliation of historical non-GAAP financial measures, the amounts of which could be material.

    NEOGEN CORPORATION

    RECONCILIATION OF NET(LOSS) INCOME TO ADJUSTED EBITDA

    (In thousands, except for percentages)

    (Preliminary Unaudited)







    Three months ended November 30,





    Six months ended November 30,







    2024





    2023





    2024





    2023



    Net loss



    $

    (456,282)





    $

    (3,487)





    $

    (468,891)





    $

    (1,984)



    Income tax benefit





    (20,290)







    (260)







    (23,290)







    (100)



    Depreciation and amortization





    30,049







    29,469







    59,849







    58,203



    Interest expense, net





    17,367







    16,169







    34,989







    32,835



    EBITDA



    $

    (429,156)





    $

    41,891





    $

    (397,343)





    $

    88,954



    Share-based compensation





    4,819







    3,512







    8,801







    6,150



    FX transaction loss on loan and other revaluation (1)





    384







    1,002







    64







    712



    Certain transaction fees and integration costs (2)





    3,593







    4,688







    8,715







    6,639



    Restructuring (3)





    9,568







    1,856







    9,938







    2,415



    Goodwill impairment





    461,390







    —







    461,390







    —



    Contingent consideration adjustments





    —







    150







    —







    450



    ERP expense (4)





    716







    2,075







    2,551







    2,203



    Discontinued product line expense (5)





    —







    —







    912







    20



    Other





    67







    (74)







    67







    (74)



    Adjusted EBITDA



    $

    51,381





    $

    55,100





    $

    95,095





    $

    107,469



    Adjusted EBITDA margin (% of sales)





    22.2

    %





    24.0

    %





    21.2

    %





    23.4

    %





    (1)

    Net foreign currency transaction loss associated with the revaluation of foreign denominated intercompany loans established in connection with the 3M Food Safety transaction and other non-hedged foreign currency revaluation resulting from 3M agreements.

    (2)

    Includes costs associated with the 3M transaction, including various transition agreements. During the three months ended November 30, 2024 and 2023, $2.6 million and $3.8 million are recorded within Cost of Revenues, respectively.

    (3)

    Severance, non-cash impairment, and other related exit costs primarily associated with a reduction in our global genomics business. During the three months ended November 30, 2024 and 2023, $4.8 million and $0.3 million are recorded within Cost of Revenues, respectively.

    (4)

    Expenses related to ERP implementation.    

    (5)

    Expenses associated with certain discontinued product lines.

     

    NEOGEN CORPORATION

    RECONCILIATION OF NET (LOSS) INCOME TO ADJUSTED NET INCOME

    (In thousands, except for per share)

    (Preliminary Unaudited)







    Three months ended November 30,





    Six months ended November 30,







    2024





    2023





    2024





    2023



    Net loss



    $

    (456,282)





    $

    (3,487)





    $

    (468,891)





    $

    (1,984)



    Amortization of acquisition-related intangibles





    23,174







    23,094







    46,312







    46,419



    Share-based compensation





    4,819







    3,512







    8,801







    6,150



    FX transaction loss on loan and other revaluation (1)





    384







    1,002







    64







    712



    Certain transaction fees and integration costs (2)





    3,593







    4,688







    8,715







    6,639



    Restructuring (3)





    9,568







    1,856







    9,938







    2,415



    Goodwill impairment





    461,390







    —







    461,390







    —



    Contingent consideration adjustments





    —







    150







    —







    450



    ERP expense (4)





    716







    2,075







    2,551







    2,203



    Discontinued product line expense (5)





    —







    —







    912







    20



    Other





    67







    (74)







    67







    (74)



    Estimated tax effect of above adjustments (6)





    (23,077)







    (7,953)







    (31,129)







    (14,400)



    Adjusted Net Income



    $

    24,352





    $

    24,863





    $

    38,730





    $

    48,550



    Adjusted Earnings per Share



    $

    0.11





    $

    0.11





    $

    0.18





    $

    0.22







    (1)

    Net foreign currency transaction loss associated with the revaluation of foreign denominated intercompany loans established in connection with the 3M Food Safety transaction and other non-hedged foreign currency revaluation resulting from 3M agreements.

    (2)

    Includes costs associated with the 3M transaction, including various transition agreements. 

    (3)

    Severance, non-cash impairment, and other related exit costs primarily associated with a reduction in our global genomics business.

    (4)

    Expenses related to ERP implementation.     

    (5)

    Expenses associated with certain discontinued product lines.  

    (6)

    Tax effect of adjustments is calculated using projected effective tax rates for each applicable item.

     

    NEOGEN CORPORATION

    RECONCILIATION OF GROWTH TO CORE GROWTH

    (In thousands)

    (Preliminary Unaudited)







    Q2 FY25





    Q2 FY24





    Growth



    Foreign Currency



    Acquisitions

    /

    Divestitures



    Core Revenue

    Growth

    Food Safety



    $

    164,238





    $

    164,403





    (0.1 %)



    (3.6 %)



    (0.1 %)



    3.6 %

    Animal Safety





    67,020







    65,226





    2.8 %



    0.3 %



    (0.7 %)



    3.2 %

    Total Neogen



    $

    231,258





    $

    229,629





    0.7 %



    (2.5 %)



    (0.3 %)



    3.5 %

    Contact

    Bill Waelke

    (517) 372-9200

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neogen-announces-preliminary-second-quarter-2025-results-302347474.html

    SOURCE Neogen Corporation

    Get the next $NEOG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NEOG

    DatePrice TargetRatingAnalyst
    12/19/2024$15.00Buy
    Guggenheim
    6/16/2023$22.00Overweight
    Wells Fargo
    11/22/2022Mkt Perform → Outperform
    William Blair
    7/12/2022$25.00Neutral
    Piper Sandler
    More analyst ratings

    $NEOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Woteki Catherine E bought $29,831 worth of shares (5,770 units at $5.17), increasing direct ownership by 77% to 13,244 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/25/25 4:32:35 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Borel James C bought $149,700 worth of shares (30,000 units at $4.99), increasing direct ownership by 50% to 90,474 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/25/25 2:45:19 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Boehm William T bought $26,175 worth of shares (5,000 units at $5.24), increasing direct ownership by 16% to 36,214 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/24/25 3:34:30 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    SEC Filings

    See more
    • Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NEOGEN CORP (0000711377) (Filer)

      4/22/25 4:45:23 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Neogen Corporation

      10-Q - NEOGEN CORP (0000711377) (Filer)

      4/9/25 4:04:19 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - NEOGEN CORP (0000711377) (Filer)

      4/9/25 7:06:54 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $NEOG
    Financials

    Live finance-specific insights

    See more
    • Neogen Announces Sale of Cleaners & Disinfectants Business

      Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today it has entered into a definitive agreement to sell its global cleaners and disinfectants business to Kersia Group ("Kersia"), a global leader in biosecurity, disinfection and hygiene solutions, for $130 million in cash at closing plus contingent consideration tied to the future performance of the business. The transaction is expected to be accretive to margins and close in the first quarter of the Company's 2026 fiscal year, subject to regulatory approval and customary closing conditions. The net proceeds will be used to fully repay the $100 million drawn on the Company's revolving credit facili

      4/21/25 9:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen® Announces CEO Transition

      Board has Formed Search Committee and Engaged Leading Executive Search Firm Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced that John Adent, the Company's CEO and President, will be stepping down after an eight-year career at the Company. Mr. Adent will continue to serve in his existing roles until his successor has been appointed. Neogen's Board of Directors has formed a special committee, comprising Board Chair Jim Borel, Thierry Bernard and Jeff Capello, to direct the search for the Company's next CEO and has engaged a leading global executive search firm. The special committee will also support Mr. Adent and the leadership team as they

      4/9/25 7:01:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Third-Quarter 2025 Results

      Revenue of $221.0 million. Net loss of $11.0 million; $(0.05) per diluted share. Adjusted Net Income1 of $20.9 million; $0.10 per diluted share. Adjusted EBITDA1 of $48.5 million. Updating full-year guidance. 1 Non-GAAP financial measures; see explanations and reconciliations that follow. Neogen Corporation (NASDAQ:NEOG) announced today the results of the third quarter ended February 28, 2025. "During the third quarter, we continued to make good progress on the integration and saw a solid underlying performance in our Food Safety segment," said John Adent, Neogen's President and Chief Executive Officer. "The quarter was impacted by lower sample collection revenue, but we made s

      4/9/25 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Third-Quarter 2025 Results

      Revenue of $221.0 million. Net loss of $11.0 million; $(0.05) per diluted share. Adjusted Net Income1 of $20.9 million; $0.10 per diluted share. Adjusted EBITDA1 of $48.5 million. Updating full-year guidance. 1 Non-GAAP financial measures; see explanations and reconciliations that follow. Neogen Corporation (NASDAQ:NEOG) announced today the results of the third quarter ended February 28, 2025. "During the third quarter, we continued to make good progress on the integration and saw a solid underlying performance in our Food Safety segment," said John Adent, Neogen's President and Chief Executive Officer. "The quarter was impacted by lower sample collection revenue, but we made s

      4/9/25 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Third-Quarter Earnings Release Date

      LANSING, Mich., March 20, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) will issue its third-quarter earnings release before the opening of the market on Wednesday, April 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing:Toll-Free - North America: 1-800-549-8228International: (+1) 646-564-2877Conference ID: 63045 The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/inves

      3/20/25 4:15:00 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Preliminary¹ Second-Quarter 2025 Results

      Revenue of $231.3 million.Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share.Adjusted Net Income2 of $24.4 million; $0.11 per diluted share.Adjusted EBITDA2 of $51.4 million.Updating full-year guidance.LANSING, Mich., Jan. 10, 2025 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) announced today the preliminary results of the second quarter ended November 30, 2024. "The second quarter reflected steady progress, as we saw improvement across the business compared to the first quarter, with core revenue growth accelerating in both of our seg

      1/10/25 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Neogen Corporation

      SC 13G - NEOGEN CORP (0000711377) (Subject)

      11/14/24 4:28:12 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Neogen Corporation

      SC 13G - NEOGEN CORP (0000711377) (Subject)

      11/14/24 11:16:20 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

      SC 13G/A - NEOGEN CORP (0000711377) (Subject)

      2/13/24 5:09:41 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Neogen with a new price target

      Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00

      12/19/24 8:18:19 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Wells Fargo initiated coverage on Neogen with a new price target

      Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00

      6/16/23 7:34:39 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen upgraded by William Blair

      William Blair upgraded Neogen from Mkt Perform to Outperform

      11/22/22 8:02:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Moylan John Patrick exercised 4,558 shares at a strike of $5.15 and covered exercise/tax liability with 1,603 shares, increasing direct ownership by 30% to 12,955 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      5/2/25 1:48:58 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CEO Adent John Edward exercised 2,112 shares at a strike of $5.16, increasing direct ownership by 0.78% to 271,276 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/29/25 1:39:59 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Operating Officer Jones Douglas Edward exercised 845 shares at a strike of $5.16 and covered exercise/tax liability with 291 shares, increasing direct ownership by 0.78% to 71,713 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/29/25 1:34:22 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Leadership Updates

    Live Leadership Updates

    See more
    • Neogen® Announces CEO Transition

      Board has Formed Search Committee and Engaged Leading Executive Search Firm Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced that John Adent, the Company's CEO and President, will be stepping down after an eight-year career at the Company. Mr. Adent will continue to serve in his existing roles until his successor has been appointed. Neogen's Board of Directors has formed a special committee, comprising Board Chair Jim Borel, Thierry Bernard and Jeff Capello, to direct the search for the Company's next CEO and has engaged a leading global executive search firm. The special committee will also support Mr. Adent and the leadership team as they

      4/9/25 7:01:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • Neogen Announces the Appointment of New Board Member

      LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its

      10/1/24 8:45:00 AM ET
      $NEOG
      $QGEN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)